Autoimmune and inflammatory diseases are characterized by aberrant immune responses. The immunoproteasome was proposed as a target for such Th cell-mediated diseases due to its role in the activation, differentiation and function of T cells. Even though many studies demonstrated reductions in Th17 cells upon immunoproteasome inhibition, it is still unclear if the differentiation or survival of these cells is affected. Therefore, this study used DSS-induced colitis and house dust mite airway inflammation mouse models to investigate the effect of immunoproteasome inhibition on Th17 cells and Tregs at different time points. Th17 cells were almost abolished when immunoproteasome inhibition was applied continuously in DSS-induced colitis. In contrast, immunoproteasome inhibition did not decrease levels of already differentiated Th17 cells and did not enhance Treg induction. Dendritic cells were barely affected by immunoproteasome inhibition. Moreover, immunoproteasome inhibition reduced T cell activation in vitro and in vivo, suggesting impaired activation as the underlying mechanism for reduced Th17 differentiation. In conclusion, immunoproteasome inhibition reduces Th17 differentiation by impairing the activation of naïve T cells, but it does not affect the survival of already-differentiated Th17 cells and Tregs.
The immunoproteasome (IP) is a specialized form of the 26S proteasome, in which the catalytic subunits β1c, β2c, and β5c of the standard proteasome are replaced by LMP2, MECL-1, and LMP7. The IP is constitutively expressed in hematopoietic cells and its expression in non-hematopoietic cells can be induced by IFN-γ. The IP plays a crucial role in different immune functions, including MHC class-I ligand generation, cytokine production, and T helper cell differentiation. Selective inhibition of the IP has shown therapeutic benefits in treating different autoimmune diseases in pre-clinical animal models. However, the effect of IP inhibition on antibody production in viral infection and vaccination has remained underexplored. In this study, we used ONX 0914, an LMP7/LMP2-selective inhibitor of the IP, to study the effect of IP inhibition on B cells and antibody production. In vitro, continuous exposure to ONX 0914 in a human B cell lymphoma cell line and primary murine B and plasma cells led to poly-ubiquitinated protein accumulation, increased apoptosis, reduced antibody secretion, and impaired immunoglobulin class-switch. However, induction of virus neutralizing antibodies was not affected in IP inhibitor-treated mice. Furthermore, IP inhibition neither impaired vaccine-induced antibody responses, nor affected different B cell populations in two different vaccination models. These findings suggest that IP inhibition does not compromise vaccination efficacy and anti-viral humoral immunity, supporting the potential of IP-targeted therapies for autoimmune diseases.
Here, we present a protocol to study social transmission of stress in group-housed mice using restraint stress. We describe steps for exposing mice to restrained conspecifics separated by an acrylic divider to induce indirect stress responses. We detail procedures for acute and chronic paradigms, followed by behavioral, physiological, and immunological assessments in both restrained and bystander mice. The protocol allows for the investigation of sensory and social mechanisms underlying stress contagion, while excluding visual cues. For complete details on the use and execution of this protocol, please refer to Horvath et al.1.